US6402683063
US6402683063
Nektar Therapeutics
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 55.232.000 | 98.427.000 | 43.9% |
| Cost of Revenue | -- | 30.686.000 | -- |
| Gross Profit | 55.232.000 | 67.741.000 | 18.5% |
| 186.003.000 | 197.659.000 | 5.9% | |
| Operating Income | -130.771.000 | -129.918.000 | 0.7% |
| Pretax Income | -155.487.000 | -119.200.000 | 30.4% |
| Net Income Common Stockholders | -164.076.000 | -118.961.000 | 37.9% |
| -- | -- | -- | |
| -- | -- | -- |